Moleculin Biotech (MBRX) Prices 14.27M Share Common Offering at $4.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Moleculin Biotech (MBRX) Announces Proposed Underwritten Public Offering
February 2, 2021 4:23 PM ESTMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it intends to offer and sell shares of common stock (or pre-funded warrants... More
Moleculin Biotech (MBRX) Surges 45% on Early Data
February 2, 2021 7:51 AM ESTMoleculin Biotech (NASDAQ: MBRX) surges 45% announces 100% survival in Osteosarcoma Lung Metastases animal model.
... MoreMoleculin Biotech (MBRX) Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
February 2, 2021 7:41 AM ESTMoleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. This appears to be the result of the high cytotoxic potential of Annamycin previously demonstrated in vitro against sarcoma cells in combination with its high uptake by the lungs where the tumors in this study are localized. Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited... More
Moleculin Biotech (MBRX) PT Raised to $29 at Roth Capital, Adjusting PT After 1 To 6 Stock Split
February 1, 2021 10:30 AM ESTRoth Capital analyst Jonathan Aschoff raised the price target on Moleculin Biotech (NASDAQ: MBRX) to $29.00 (from $5.00) while maintaining a Buy rating.
... MoreMoleculin Biotech (MBRX) Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial
February 1, 2021 7:33 AM ESTMoleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has signed an agreement with Catalyst Clinical Research (Catalyst), a contract research organization, to manage its US clinical trial to study the ability of Annamycin to treat soft tissue sarcoma (STS) that has metastasized to the lungs.
Soft tissue sarcomas are the most common form of sarcoma, accounting for an estimated... More
